Announcements Trials
Browse Landscape

Phase

Phase 1/2 1Phase 1 1

Status

Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other solid neoplasm 1Lymphoid 1

Conditions

Solid Tumor Cancer 1Lymphoma, Non-Hodgkin 1Hodgkin Disease 1

Interventions

pembrolizumab 1033Carboplatin 971Paclitaxel 942Gemcitabine 799Cisplatin 757Docetaxel 698Bevacizumab 637Nivolumab 520Pemetrexed 507Capecitabine 475Cyclophosphamide 473Fluorouracil 425Dexamethasone 410Rituximab 391Oxaliplatin 352Injections 347Trastuzumab 314atezolizumab 312Cetuximab 291Leucovorin 290Irinotecan 271130-nm albumin-bound paclitaxel 257Prednisone 251Ipilimumab 244Doxorubicin 241Lenalidomide 231Fulvestrant 226fludarabine 219durvalumab 211Erlotinib Hydrochloride 196

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
INDUSTRY × SB 743921 × Clear all
NCT00343564 2020-01-13

A Study of SB-743921 in Non-Hodgkin Lymphoma and Hodgkin Lymphoma

Cytokinetics

Phase 1/2 Completed
68 enrolled 26 charts
Lymphoid

Hodgkin Disease, Lymphoma, Non-Hodgkin

NCT00136513 2008-10-16

SB-743921 In Patients With Solid Tumors

GlaxoSmithKline

Phase 1 Completed
30 enrolled
Other solid neoplasm

Solid Tumor Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡